Sirnaomics (2257) Stock Overview

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs in the United Sates, the People's Republic of China, and Hong Kong. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat remodeling. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP702 for the treatment of influenza; RIM730 COVID-19 vaccine; and STP122G to treat anticoagulation/thrombosis. In addition, the company is developing STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement-mediated diseases. Sirnaomics Ltd. was founded in 2007 and is headquartered in Germantown, Maryland.